Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Copper price pushing towards $100000 a tonne. Looks highly likely to make a new All Time High soon.
Asiamet continues to be valued below 20£million. For a company with an advanced copper project that will generate 25,0000 tonnes Copper Cathode annually the level of cash flow is enormous.
I highly suspect we will see the first offer for KSK come in shortly.
Asiamet has been leaky for years.
Current volume increase and share price movement upwards suggests something of significance is coming.
We all know that this could easily double on one rns.
Downside risk is minimal based on market cap being so low.
It’s a compelling short term trade.
BKM NVP on the detailed & refined feasibility study is well above $200m at these copper prices. BKM sits in the KSK district which is part of the Asiamet assets. KSK has another 20+ project targets with the other major one being BKZ which again is detailed.
With a company valuation at 15 £million it is a compelling takeover target with one of the few global near term copper projects so advanced.
Anyone buying at these levels of share price would double their money easily and likely do much more than that.
Selling has now moved to buying and can easily see this stock moving really fast with such a low free float.
One of the best, if not the best value, junior miners on LSE/AIM.
Investors may have been rocked by the 50p placing, but it raised more than expected & funds the company for two years. I think now it will quickly move back up towards £1 as new investors come on board.
This is not a time to ponder and wait. It will move really fast once it gets going.
This is Beutong:
Contained metal in Resource on a 100% basis comprises 2.43Mt (5.3BIb) copper, 2.11Moz gold and 20.9Moz silver (1.95Mt (4.30Blb) copper, 1.69Moz gold and 16.73Moz silver on an 80% attributable basis)
The Beutong porphyry and skarn system(s) remains open to the east, west and at depth. The deepest drilling completed to date has intersected porphyry mineralisation to around 800 metres below surface and approximately 200-300 metres below the depth of Resource delineation drilling completed to date.
Strong copper, gold and molybdenum grades and the presence of highly mineralised chalcopyrite-bornitemagnetite bearing breccia clasts proximal to a large magnetic body modelled at depth below current drilling highlight excellent potential for the discovery of a high grade core similar to that seen in world class porphyry systems such as Wafi Golpu, PNG (Newcrest) and Cascabel, Ecuador (Solgold
The positive out of today is that they have taken more money because the placing was oversubscribed. This now gives them a 12 month cash runway, which is time to really advance the data.
For all shareholders, unless they decide to sell now, this should give the platform for the share price to gradually recover some ground.
Good luck to all retail investors now.
I said last week they needed to raise £25-30million & they have only got away £13million .
This means they will be back with more dilution within 6 months.
They simply have to keep raising money to pay the huge cash outlay.
No real technical support now until 50p.
Market just does not get the valuation of this business at £200m. Also does not believe they can get funding away unless at a heavy discount.
Thought it might consolidate around 72p but too much selling for that to happen.
Some investors I suspect panic selling as they realise this is early stage biotech & you can get hugely diluted or even lose everything.
In investing you must never be an Ostrich. You cannot bury your head in the sand. You have to listen to all opinions & you then have to take a balanced view.
Just pumping out messages about how good the data is does not solve the funding issue.
Don’t get me wrong if I was already invested I would hold here, but I would not be adding until funding is resolved.
Just my opinion. Shout it down if it makes you feel better.
Unless there is significant news or they close funding then before any meaningful & sustained rise in this stock will only come after volume drops & we see a period of consolidation.
At the moment this wants to retest the recent low of 72p & likely it then puts in another low.
Funding is a major issue for all biotechs however good the data.
It either double bottoms at 72p now or drops a lot further.
The issue remains the same. The enormous market cap for a business that’s not even anywhere near phase 2 data closure.
People need to read the success rates of early stage biotech’s. The number that actually get through phase 2 & 3 then approval is tiny.
Anyone invested here needs to understand the risk of losing everything.
In the meantime they need to raise cash.
The winners today will be the short term traders who bought in on the back of this mornings pump. They will then sell into this dead cat bounce.
Anyone saying the bottom is in is calling that way too early.
Next week will be a slow drift back down unless some big news lands.
Key technical support was broken so now support is 43p. The 52 week low of 83p looks like it’s about to break.
Have to assume now the cash raise will need to be £30million minimum so a dilution of around 20-30% for all shareholders.
There is always an outside chance of a commercial deal to get cash into the business, but the issue is the company is still valued at £240m.
It will be a painful period now until cash is raised.
Since the recent high just above 160p in October the share price has almost halfed despite all the news. It has recently fell through an important support level so technically as well it’s in decline.
Market cap closer to £50-75m makes this attractive but
not the current £260m.
For those playing the long game best to switch the share price off & return again later this year after the dilution has taken place.
The figures shout out cash injection is needed soon.
At 30 June the company had cash and short term deposits of £26m. Burn rate is around £2m per month so they will need to raise more cash within the next couple of months as dropping below £5-6m in cash would mean management would have to take steps to radically reduce overheads.
I do not expect the business to struggle to raise more capital funding, but the issue will be at what valuation. With biotech investment market currently difficult you can draw your own conclusions.
The smart move is to sell now and then buy back in after funding secured.
The issue with these early stage biotech businesses is they require huge levels of funding , that often leads to shareholder dilution. They can face small or large setbacks along the way.
AVCT has outpaced itself & now sits at a market valuation of £280m which is far too high for a company at this early stage, despite the positive news so far.
The reality is getting through phase 2 & then 3 followed by regulators approval is years away.
Anyone investing in this company needs to have a very long view unless you are just short term trading it for a small % gain.
Arguing on this board will make no difference to the share price as more than £1m is being traded in stock daily. Hope this perspective may help peoples decision on whether to hold for the long term or not.
Ross is a seasoned biotech pro and you can guarantee he is working up something significant in the background.
The data shows they have something nobody else does.
They also have a world class stem cell production facility in Wales which alone is worth 3-5 times current market cap.
Last two trading days has seen a buyer come into Reneuron. Someone has started to build a position. £2million market cap now makes this a real takeover target.
So the Chairman has now not bought in open market for more than two weeks. He has been actively buying regularly. Maybe the company has moved into a closed period due to discussions with a potential buyer or a material new commercial deal.
So the brand is Saudi money. Saudi’s want to become the esports global capital & Guild are in there early.
Suspect this is highly significant for this company with a currently valuation of just £4m